{
  "id": "5880dba9c872c95565000009",
  "type": "factoid",
  "question": "Which enzyme is inhibited by ribociclib?",
  "ideal_answer": "Ribociclib is inhibitor of cyclin D-cyclin-dependent kinase 4/6 (CDK 4/6). It is used for breast cancer treatment.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26303211",
    "http://www.ncbi.nlm.nih.gov/pubmed/27729458",
    "http://www.ncbi.nlm.nih.gov/pubmed/27017286",
    "http://www.ncbi.nlm.nih.gov/pubmed/25941111",
    "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
    "http://www.ncbi.nlm.nih.gov/pubmed/27030077",
    "http://www.ncbi.nlm.nih.gov/pubmed/27493615",
    "http://www.ncbi.nlm.nih.gov/pubmed/27496135",
    "http://www.ncbi.nlm.nih.gov/pubmed/26830312",
    "http://www.ncbi.nlm.nih.gov/pubmed/25848011",
    "http://www.ncbi.nlm.nih.gov/pubmed/27717303",
    "http://www.ncbi.nlm.nih.gov/pubmed/27810861",
    "http://www.ncbi.nlm.nih.gov/pubmed/27542767",
    "http://www.ncbi.nlm.nih.gov/pubmed/26053278",
    "http://www.ncbi.nlm.nih.gov/pubmed/26995305",
    "http://www.ncbi.nlm.nih.gov/pubmed/27336726",
    "http://www.ncbi.nlm.nih.gov/pubmed/26390342",
    "http://www.ncbi.nlm.nih.gov/pubmed/27087139",
    "http://www.ncbi.nlm.nih.gov/pubmed/25876993",
    "http://www.ncbi.nlm.nih.gov/pubmed/26896604"
  ],
  "snippets": [
    {
      "text": "Three CDK 4/6 inhibitors have been investigated for the treatment of HR(+) breast cancer, including palbociclib (PD 0332991), ribociclib (LEE011), and abemaciclib (LY2835219). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26303211",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The CDK 4/6 inhibitors are a novel class of therapeutics that target the CDK 4/6 kinases that promote transition through the cell cycle. Currently, palbociclib (PD0332991, Pfizer), abemaciclib (LY2835219, Lilly) and ribociclib (LEE011, Novartis) are being investigated in clinical trials. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SUMMARY: Palbociclib, abemaciclib and ribociclib have demonstrated very promising clinical activity in breast cancer, liposarcoma, mantel cell lymphoma and melanoma. Moreover, CDK4/6 inhibitors have shown promising preclinical activity in glioblastoma, renal and ovarian cancer models that may provide directions for their future clinical development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26642065",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, three selective CDK4/6 inhibitors have been approved or are in late-stage development: palbociclib (PD-0332991), ribociclib (LEE011), and abemaciclib (LY2835219).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27017286",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The combination of antiestrogen therapy and ribociclib, an investigational CDK4/6 inhibitor, led to improved outcomes in women with metastatic HR-positive, HER2-negative breast cancer, according to findings presented at a meeting of the European Society for Medical Oncology. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27810861",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES: Cyclin D-cyclin-dependent kinase (CDK) 4/6-inhibitor of CDK4/6-retinoblastoma (Rb) pathway hyperactivation is associated with hormone receptor-positive (HR+) breast cancer (BC). This study assessed the biological activity of ribociclib (LEE011; CDK4/6 inhibitor) plus letrozole compared with single-agent letrozole in the presurgical setting",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27336726",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Importantly, 2 other CDK4/6 inhibitors, abemaciclib (LY2835219; Lilly) and ribociclib (LEE011; Novartis), are in the late stage of clinical development. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493615",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "After noting an inverse correlation with sensitivity to ribociclib (CDK4/6 inhibitor), we studied the combinatorial effect of these two agents using proliferation assays, cell cycle analysis, Ki67 immunostaining, timelapse microscopy and xenograft studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27729458",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Methods In this randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy and safety of the selective CDK4/6 inhibitor ribociclib combined with letrozole for first-line treatment in 668 postmenopausal women with HR-positive, HER2-negative recurrent or metastatic breast cancer who had not received previous systemic therapy for advanced disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27717303",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Three selective CDK4/6 inhibitors, palbociclib (Ibrance; Pfizer), ribociclib (Novartis), and abemaciclib (Lilly), are in various stages of development in a variety of pRb-positive tumor types, including breast cancer, melanoma, liposarcoma, and non-small cell lung cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941111",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493615",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Targeted inhibition of CDK4/6 pathway by small-molecule inhibitors palbociclib (PD-0332991) and ribociclib (LEE011) resulted in inhibition of cell-cycle progression, amelioration of kidney injury, and improved overall survival. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25848011",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493615",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004798"
  ],
  "exact_answer": "cyclin D-cyclin-dependent kinase 4/6, CDK4/6"
}